SCHEMBL4466743

SCHEMBL4466743

O=c1c(Br)c(Nc2ccc(F)cc2F)ccn1Cc1cccc(F)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.60
MAPT P10636 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
POLB P06746 1/20 0.45
THRB P10828 1/20 0.45
PTGER3 P43115 1/20 0.43
PKM P14618 1/20 0.42
PDE1C Q14123 2/20 0.41
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
DBH P09172 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476536 0.88 MAPK14 (0.55) MAPK14MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL4478413 0.84 MAPK14 (0.56) MAPK14MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL4376114 0.84 MAPK14 (0.64) MAPK14MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL4474073 0.83 MAPK14 (0.57) MAPK14SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL4480210 0.82 MAPT (0.56) MAPK14MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL4389631 0.81 ALDH1A1 (0.55) MAPK14SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL3521065 0.81 MAPK14 (0.52) MAPK14MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL4467899 0.80 MAPT (0.54) MAPK14MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL4378804 0.80 MAPK14 (0.56) MAPK14MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL4385079 0.80 MAPK14 (0.51) MAPK14MAPTSMN1; SMN2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US claimed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPK14 41/4885MAPT 2803/4885SMN1; SMN2 1433/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885MAPT 2543/4885SMN1; SMN2 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.